Proud to share my latest first authorship! This is the first clinical trial testing IV #arketamine for #bipolar depression. Subjects received two infusions one week apart—0.5 mg/kg first and then 1 mg/kg, showing rapid-acting antidepressant properties.

https://doi.org/10.1016/j.jpsychires.2023.06.028

Excited to share our pioneer pilot crossover #RCT testing arketamine for treatment-resistant #depression (TRD). Racemic #ketamine is a mixture of #arketamine and #esketamine. Preclinical data and one open-label human trial suggest arketamine might exert a more potent and longer-lasting #antidepressant effect with fewer side effects. However, arketamine was not superior to #placebo for #TRD in our study.

https://doi.org/10.1016/j.jad.2023.02.151

#Psychiatry #ClinicalTrials #Fediscience #PsychMastodon